The estimated Net Worth of Vickie L Capps is at least $389 millier dollars as of 28 November 2022. Ms. Capps owns over 42,242 units of Nuvasive Inc stock worth over $135,150 and over the last 10 years she sold NUVA stock worth over $4,224. In addition, she makes $250,057 as Independent Director at Nuvasive Inc.
Sign up
Ms. Capps NUVA stock SEC Form 4 insiders trading
Vickie has made over 6 trades of the Nuvasive Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 42,242 units of NUVA stock worth $4,224 on 28 November 2022.
The largest trade she's ever made was selling 42,242 units of Nuvasive Inc stock on 28 November 2022 worth over $4,224. On average, Vickie trades about 1,917 units every 70 days since 2014. As of 28 November 2022 she still owns at least 3,400 units of Nuvasive Inc stock.
You can see the complete history of Ms. Capps stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vickie Capps biography
Vickie L. Capps serves as Independent Director of the Company. Ms. Capps is currently a Senior Advisory Board Member of Consonance Capital Partners, a healthcare investment firm. Ms. Capps previously served as chief financial officer of several public and private companies. From 2002 to 2013, Ms. Capps served as the Executive Vice President, Chief Financial Officer and Treasurer at DJO Global, Inc. a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, where she was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. Earlier in her career, she served as a senior audit and accounting professional at Ernst & Young LLP. Ms. Capps’ extensive financial expertise and executive leadership experience as a former chief financial officer provide valuable financial and accounting experience to our Board.
What is the salary of Vickie Capps?
As the Independent Director of Nuvasive Inc, the total compensation of Vickie Capps at Nuvasive Inc is $250,057. There are 8 executives at Nuvasive Inc getting paid more, with J. Christopher Barry having the highest compensation of $5,425,440.
How old is Vickie Capps?
Vickie Capps is 58, she's been the Independent Director of Nuvasive Inc since 2015. There are 3 older and 15 younger executives at Nuvasive Inc. The oldest executive at Nuvasive Inc is Donald Rosenberg, 69, who is the Independent Director.
What's Vickie Capps's mailing address?
Vickie's mailing address filed with the SEC is 3854 AMERICAN WAY, SUITE A, , BATON ROUGE, LA, 70816.
Insiders trading at Nuvasive Inc
Over the last 21 years, insiders at Nuvasive Inc have traded over $60,917,905 worth of Nuvasive Inc stock and bought 185,079 units worth $8,372,956 . The most active insiders traders include Jesse I Treu, James C Blair et Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of $415,308. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth $72,703.
What does Nuvasive Inc do?
nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through
What does Nuvasive Inc's logo look like?
Complete history of Ms. Capps stock trades at Amedisys, Nuvasive Inc, Otonomy Inc et Silverback Therapeutics
Nuvasive Inc executives and stock owners
Nuvasive Inc executives and other stock owners filed with the SEC include:
-
J. Christopher Barry,
Chief Executive Officer, Director -
J. Christopher Barry,
CEO & Director -
Nathaniel Sisitsky,
Senior Vice President, General Counsel, Corporate Secretary -
Matthew K. Harbaugh,
Exec. VP & CFO -
Gregory Lucier,
Chairman of the Board -
Nathaniel B. Sisitsky Esq.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Lucas Vitale,
Sr. VP & Chief HR Officer -
Donald Rosenberg,
Independent Director -
Daniel Wolterman,
Independent Director -
Vickie Capps,
Independent Director -
Leslie Norwalk,
Independent Director -
R. Scott Huennekens,
Independent Director -
Robert Friel,
Independent Director -
John DeFord,
Independent Director -
Suzanne Hatcher,
Vice President, Internal & External Affairs -
Dale Wolf,
Senior Vice President - Global Operations -
Massimo Calafiore,
Executive Vice President - Global Business Units -
Brent Boucher,
Executive Vice President - Global Commercial -
Lucas Vitale,
Chief Human Resource Officer -
Matthew Harbaugh,
Executive Vice President, Chief Financial Officer -
Marc Rosenbaum,
VP, Corp. Controller & Chief Accounting Officer -
Michael Farrington,
VP of Corp. Marketing, Brand & Communication -
Juliet C. Cunningham,
VP of Investor Relations -
Ryan Donahoe,
Chief Technology Officer -
Dale A. Wolf,
Sr. VP of Global Operations -
Lisa Pecora,
VP & Head of Global Commercial Fin. -
Frank Middeke,
Managing Director of DACH -
Sean Freeman,
Sr. VP of Strategy & Corp. Devel. -
Johnson Lai,
Chief Information Officer -
Jereme M Sylvain,
Chief Accounting Officer -
Jack R Blair,
Director -
Peter Michael Leddy,
Director -
Edmund J Roschak,
CEO, NuVasive Spec. Orthopedic -
Dan Wolterman,
Director -
Michael D Ohalleran,
Director -
Lesley H Howe,
Director -
Peter C Farrell,
Director -
Joan Stafslien,
EVP and General Counsel -
Quentin S. Blackford,
CFO and CAO -
Cox Carol,
EVP Strategy, Corp Dev -
Tyler Lipschultz,
EVP, Biologics -
Andrew C. Morton,
SVP, CHRO -
Matthew Link,
President -
Rajesh Asarpota,
CFO -
Paul Mc Clintock,
President, U.S. Commercial -
Stephen Rozow,
EVP, Global Process -
Jeffrey P Rydin,
Senior V.P., U.S. Sales -
Jason Hannon,
VP, Legal Affairs & Secretary -
Patrick Miles,
Senior VP, Marketing -
Kevin C Oboyle,
CFO and Executive VP -
James C Blair,
Director -
James J Skinner,
VP,Strategic Sales Development -
Jonathan Spangler,
VP & Chief Patent Counsel -
G Bryan Cornwall,
VP, Research & Development -
Hansen A Yuan,
Director -
Arda Minocherhomjee,
Director -
Blair Capital Management Vi...,
-
Perkins Caufield & Byers Vi...,
10% owner -
Joseph Lacob,
Director -
G Rogan Fry,
Sr. V. P., Corp. Development -
Viii Associates Lp Kpcb,
10% owner -
Life Sciences Zaibatsu Fund...,
10% owner -
Iv Associates Lp Dp,
10% owner -
Jesse I Treu,
10% owner -
Kathleen K Schoemaker,
10% owner -
Brian H Dovey,
10% owner -
Vii Associates Lp Kpcb,
10% owner -
De Depot Et Placement Du Qu...,
10% owner -
Management Partners Iv Lpen...,
-
Partners Iv Lp Domain,
10% owner -
Viii Founders Fund L P Kpcb,
10% owner -
Russell Powers,
Exec. VP Sales Int'l Ops -
Eileen M More,
Director -
Keith Valentine,
President -
Alexis V Lukianov,
CEO and Chairman -
Michael E Paolucci,
Exec. V.P., Global HR -
Craig E Hunsaker,
SVP, Global Human Resources -
Richard Iii Treharne,
Director -
Michael Lambert,
CFO and Executive VP -
Robert J Hunt,
Director -
Siddhartha Kadia,
Director -
Amy Belt Raimundo,
Director -
Michael Farrington,
SVP, People and Culture -
Marc W. Rosenbaum,
Chief Accounting Officer